Lonza has expanded its human stem cell offerings to provide human cord blood CD34+ haematopoietic stem cells (CB-CD34+ HSCs) in large batch sizes, meeting a rapidly expanding market need.
CB-CD34+ HSCs are the preferred cell choice for creating humanised mouse models, which are critical for preclinical safety testing of a range of immunotherapies. The new offering enables mouse model developers and researchers to increase cohort sizes for bolstered model-creating capacity, simplify HLA-matched model creation, and unlock cost and time efficiencies.
Context
Humanised mice are a powerful tool for exploring how novel cancer biotherapies interact with a human-specific immune system comprising different and interacting cell types. Across the market, there is a lack of large batch sizes of these cells, restricting the number of humanised mice that can be generated per cell lot.
In addition, to maximise in vivo predictivity and accuracy of results, it is beneficial for mouse models to be carefully HLA matched to the grafted tumour tissue. Without ready-typed cells available, companies face lengthy in-house HLA screening that can add weeks to timelines, with no guarantee that an unscreened batch will contain the desired HLA type.
Lonza’s customers can now create larger mouse model cohorts of the exact HLA-type they need, expanding testing throughput capabilities and unlocking predictive results more quickly and at a significantly lower cost. The breadth of Lonza’s inventory will also allow researchers to obtain all their CB-CD34+ HSCs from a single supplier, ensuring consistency and reliable quality in their processes.
Official comments
Aurita Menezes, Global Product Manager at Lonza, said: “Isolating high-purity CD34+ stem cells from cord blood is incredibly complex, leaving most vendors unable to deliver the lot size and continuous supply required — even without HLA typing. Lonza’s technological know-how in this domain means it is leading the market with this new offering. Through this, we’re uniquely placed to accelerate routes to success for customers, further bolstering our ability to help deliver safe and affordable biotherapies to patients faster.”
